Status:
RECRUITING
Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cervical Cancer
CIN2
Eligibility:
FEMALE
25+ years
Phase:
NA
Brief Summary
The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women. Cervical cancer occurs when women are infected w...
Detailed Description
Invasive cervical cancer is a significant health burden in low and middle income countries. HIV-infected women in Africa are particularly affected and have an estimated invasive cervical cancer risk ...
Eligibility Criteria
Inclusion
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
- Confirmed HIV-1 infection
- Age 25 years and older.
- Be willing and able to provide written informed consent.
Exclusion
- Pregnant or intend to become pregnant within 90 days of enrollment
- Have been screened for cervical cancer within the preceding year (365 days)
- Have an active sexually transmitted infection (STI; women may participate once treated)
- Have a surgically absent cervix
- Have a history of cervical cancer
- have been vaccinated against HPV.
Key Trial Info
Start Date :
May 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05413798
Start Date
May 11 2023
End Date
August 1 2026
Last Update
June 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospital
Westdene, Johannesburg, South Africa, 2092